Our study enrolled 35 patients, including 10 PME patients with seven monogenic and three mitochondrial DNA (mt-DNA) variants, seven patients with SCN1A variants, six patients with CHD2 variants, 11 patients with other monogenic variants, and one patient with a CNV. This evidence concerns the gene SCN1A and progressive myoclonus epilepsy.